GI Stool Testing Market Analysis

GI Stool Testing Market Analysis

To get key market trends

  Download Free Sample

Based on product type, the GI stool testing market is segmented as consumables and analyzers. The consumables segment was valued at over USD 376 million in 2022. This segment share is primarily attributed to a significant increase in the preference for GI disease diagnostic reagents and test kits that are used to examine a range of GI-health issues such as infection, inflammatory bowel disease, and cancer among others by diagnosing & screening.
 

Market players are emphasizing on the designing of reagents to address the growing and evolving needs for GI testing in diagnostics centers and hospitals. The ongoing R&D activities are focused to deliver superior quality & excellent performance consumables that are utilized in GI stool testing for most demanding applications.
 

Based on test type, the GI stool testing market is segmented as occult blood test, ova and parasites test, bacteria test, fecal biomarkers test, and others. Fecal occult blood test (FOBT) segment held a dominant revenue share and was valued at over USD 281 million in 2022 and is expected to witness a significant growth trend during the analysis period. This is primarily attributed to a significant increase in the preference for early diagnosis and better therapeutic results among patient suffering from gastrointestinal issues such as cancer, polyps, ulcers, or haemorrhoids.  
 

The presence of blood in the stool sample indicates bleeding in the digestive tract and is considered as initial phase of the colorectal cancer. Some of the major causes of bleeding bladder include polyps, haemorrhoids, diverticulosis, ulcers, colitis, etc. For instance, according to European Crohn’s and Colitis Organisation (ECCO) data, in 2020, the incidence rate of ulcerative colitis in Europe was estimated to be around 2.4 to 44 per 100,000 individuals and is expected to rise at a steady pace. Therefore, in order to test and detect the occurrence of gastrointestinal complications among patients, fecal occult blood test (FOBT) is increasingly preferred by several healthcare professionals.
 

Based on application, the GI stool testing market is segmented as infection, inflammatory bowel disease, gastroesophageal reflux disease (GERD), cancer and others. Gastrointestinal infection segment dominated the market with more than 38% revenue share in 2022 and is forecasted to witness a similar trend during the analysis period. This is attributable to the growing prevalence of GI infection and preference for technologically advanced GI diagnostic tests, etc.  
 

Moreover, benefits associated with testing such as reliability in disease screening and reduction in the severity of infection with a better diagnosis are forecasted to positively impact the industry growth. Recent research studies have observed that H. pylori cause the majority of gastric ulcers. The highest incidence rate in developed, as well as some developing regions, is further augmenting the product adoption.
 

Based on distribution channel, the GI stool testing market is segmented as the hospital & clinics pharmacies, brick & mortar, and e-commerce. The brick & mortar stores segment is estimated to progress at substantial growth rate to reach USD 538 million by end of 2032. This substantial segment share is owing to several advantages offered by the medical retail stores in diagnostic tests distribution including the availability of a wide array of tests and substantial discounts.
 

Additionally, various market players are focusing on marketing products through medical retail stores that increase the salability of a wide variety of product, thus propelling segmental growth. Some medical retail stores also offer educational programs for precise product awareness and focus on combating health issues including GI diseases, etc. Moreover, well-defined safety, effective services, and security policies are boosting the segment revenue.
 

Based on end-use, the market is segmented as hospitals & clinics, diagnostic centers, homecare settings, and others. The hospitals & clinics segment held a majority GI stool testing market share in 2022 and is projected to reach more than USD 597 million by 2032. The soaring use of novel GI stool tests in hospital & clinical settings delivering rapid and reliable outcomes is estimated to surge the patient preference for these healthcare facilities. The availability of a broad spectrum of kits and instruments for performing these tests with proven accuracy is set to drive product preference in hospitals.
 

Growing admissions with GI ailments and growing disease screening initiatives along with the accessibility to board-certified healthcare professionals are some other variables that are augmenting the segment trends positively. Furthermore, the rising disease burden in developed economies with enhanced healthcare infrastructure is projected to stimulate the diagnosis & treatment rate at hospitals.
 

U.S GI stool testing market and was valued at around USD 254 million in 2022. This high market share is primarily attributed to several factors such as the presence of major industry players, rising prevalence of gastrointestinal disorders, etc. According to the Centers for Disease Control and Prevention (CDC) data 2021, peptic ulcer affects around 4.6 million adults every year in the U.S. As per the National Ambulatory Medical Care Survey recent data, more than 54 million patients had performed diagnosis for the diseases of the digestive systems in the U.S. Thus, gastrointestinal diagnostic procedures have been significantly rising in the U.S. over the past few years.
 

Additionally, the presence of prominent players such as Abbott Laboratories, Cardinal Health, and Meridian Bioscience Inc. among others in the country are engaged in new product development & commercialization that facilitates industrial expansion in the U.S.